Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3351144
Max Phase: Preclinical
Molecular Formula: C8H12N2O7
Molecular Weight: 248.19
Molecule Type: Small molecule
Associated Items:
ID: ALA3351144
Max Phase: Preclinical
Molecular Formula: C8H12N2O7
Molecular Weight: 248.19
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C1NC(=O)[C@@]2(N1)O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2O
Standard InChI: InChI=1S/C8H12N2O7/c11-1-2-3(12)4(13)5(14)8(17-2)6(15)9-7(16)10-8/h2-5,11-14H,1H2,(H2,9,10,15,16)/t2-,3+,4-,5-,8-/m0/s1
Standard InChI Key: QRXBDPYWCAAAAI-AZDHXYLBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 248.19 | Molecular Weight (Monoisotopic): 248.0645 | AlogP: -4.00 | #Rotatable Bonds: 1 |
Polar Surface Area: 148.35 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 6 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 8.21 | CX Basic pKa: | CX LogP: -3.33 | CX LogD: -3.39 |
Aromatic Rings: 0 | Heavy Atoms: 17 | QED Weighted: 0.26 | Np Likeness Score: 1.97 |
1. Osz E, Somsák L, Szilágyi L, Kovács L, Docsa T, Tóth B, Gergely P.. (1999) Efficient inhibition of muscle and liver glycogen phosphorylases by a new glucopyranosylidene-spiro-thiohydantoin., 9 (10): [PMID:10360741] [10.1016/s0960-894x(99)00192-4] |
2. Osz E, Somsák L, Szilágyi L, Kovács L, Docsa T, Tóth B, Gergely P.. (1999) Efficient inhibition of muscle and liver glycogen phosphorylases by a new glucopyranosylidene-spiro-thiohydantoin., 9 (10): [PMID:10360741] [10.1016/s0960-894x(99)00192-4] |
3. Pastor M, Cruciani G, Clementi S.. (1997) Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships., 40 (10): [PMID:9154968] [10.1021/jm9608016] |
4. Pastor M, Cruciani G, McLay I, Pickett S, Clementi S.. (2000) GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors., 43 (17): [PMID:10966742] [10.1021/jm000941m] |
5. Zamora I, Oprea T, Cruciani G, Pastor M, Ungell AL.. (2003) Surface descriptors for protein-ligand affinity prediction., 46 (1): [PMID:12502357] [10.1021/jm011051p] |
6. Pastor M, Cruciani G, Watson KA.. (1997) A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure--activity relationship analysis., 40 (25): [PMID:9406599] [10.1021/jm970273d] |
7. Gohlke H, Klebe G.. (2002) DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein., 45 (19): [PMID:12213058] [10.1021/jm020808p] |
8. So SS, Karplus M.. (1997) Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications., 40 (26): [PMID:9435905] [10.1021/jm970488n] |
Source(1):